论文部分内容阅读
目的探讨乌司他汀联合生长抑素治疗重症急性胰腺炎的临床疗效。方法选取2010年1月~2014年1月收治的86例重症急性胰腺炎患者进行分析研究,随机为两组,每组43例,对照组患者采用生长抑素进行治疗,观察组患者采用乌司他汀联合生长抑素进行治疗,对比两组患者治疗效果。结果观察组患者治愈22例,治疗总有效率为95.35%,对照组患者治疗总有效率为65.12%,两组对比,结果具有统计学意义(P<0.05);观察组患者各项临床指标改善时间都明显优于对照组,P<0.05,具有统计学意义;且住院时间明显短于对照组(P<0.05)。观察组患者不良反应发生率明显低于对照组,P<0.05,具有统计学意义。结论采用乌司他汀联合生长抑素进行重症急性胰腺炎的治疗,能有效提高治疗效果,减轻不良反应发生率,改善患者临床症状。
Objective To investigate the clinical efficacy of ulinastatin and somatostatin in the treatment of severe acute pancreatitis. Methods Totally 86 patients with severe acute pancreatitis who were admitted from January 2010 to January 2014 were randomly divided into two groups with 43 patients in each group. The patients in the control group were treated with somatostatin. The patients in the observation group were treated with Ulsan Statins combined with somatostatin for treatment, compared two groups of patients treatment. Results The observation group was cured in 22 cases, the total effective rate was 95.35%, the total effective rate was 65.12% in the control group, the two groups were statistically significant (P <0.05); the observation group improved the clinical indicators Time were significantly better than the control group, P <0.05, with statistical significance; and hospitalization was significantly shorter than the control group (P <0.05). The incidence of adverse reactions in the observation group was significantly lower than that of the control group, P <0.05, with statistical significance. Conclusion Ulinastatin combined with somatostatin in the treatment of severe acute pancreatitis can effectively improve the therapeutic effect, reduce the incidence of adverse reactions and improve the clinical symptoms of patients.